Screener
Ligand Pharmaceuticals LGND Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's retained earnings?
- Ligand Pharmaceuticals (LGND) reported retained earnings of $583.25M in Q2 2026.
- How has Ligand Pharmaceuticals's retained earnings changed year-over-year?
- Ligand Pharmaceuticals's retained earnings increased by 26.4% year-over-year, from $461.38M to $583.25M.
- What is the long-term trend for Ligand Pharmaceuticals's retained earnings?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's retained earnings has grown at a 9.2% compound annual growth rate (CAGR), from $391.95M to $608.09M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Ligand Pharmaceuticals's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude